By Fineline Cube Jiangsu Aidea Pharmaceutical Group Co., Ltd. (SHA: 688488) announced today that China’s National Medical Products Administration (NMPA) has granted marketing approval for its darunavir product, positioning the company to compete directly with Johnson & Johnson’s established Prezista brand in China’s HIV treatment market. The protease inhibitor is indicated for HIV-1 infection in antiretroviral therapy (ART)-experienced patients aged 3 years and older (weighing at least 40 kg) with darunavir resistance-associated mutations or when genotypic testing is unavailable.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | Marketing authorization for darunavir |
| Indication | HIV-1 infection in ART-experienced patients with resistance mutations or untestable genotypes |
| Patient Population | Adults and pediatric patients ≥3 years old, ≥40 kg |
| Administration | Co-administered with ritonavir plus other antiretroviral agents |
| Approval Date | 24 Jul 2026 |
| Originator | Johnson & Johnson (original FDA approval: June 2006) |
Market Context & Competitive Landscape
- Historical Precedent: Darunavir was originally developed by Johnson & Johnson and received U.S. FDA approval in June 2006 under the brand name PREZISTA
- China Market Entry: J&J’s Prezista was first approved for import into China in September 2008, establishing a 18-year presence in the Chinese HIV market
- Combination Product: J&J’s fixed-dose combination darunavir/cobicistat (Symtuza) was approved for import into China in July 2018, offering a once-daily regimen
- Generic Competition: Aidea’s approval represents the first domestic Chinese competitor to J&J’s darunavir franchise, potentially disrupting premium pricing in the protease inhibitor segment
Therapeutic Significance
- Resistance Profile: Darunavir maintains efficacy against HIV strains resistant to other protease inhibitors, making it a critical option for treatment-experienced patients
- High Genetic Barrier: The drug’s high genetic barrier to resistance contributes to its durability as a long-term treatment option
- Pediatric Indication: Inclusion of pediatric patients (≥3 years, ≥40 kg) addresses an important unmet need in China’s pediatric HIV population
- Testing Limitations: The indication covers patients for whom HIV-1 genotypic testing cannot be conducted, expanding access in resource-limited settings
Commercial Implications
- Market Opportunity: China’s HIV treatment market continues to grow, with an estimated 1.2 million people living with HIV and increasing access to antiretroviral therapy
- Pricing Advantage: As a domestically produced product, Aidea’s darunavir is expected to offer significant cost advantages over imported Prezista, potentially accelerating market penetration
- Reimbursement Strategy: Likely inclusion in China’s National Reimbursement Drug List (NRDL) could further enhance accessibility and drive volume-based revenue
- Revenue Impact: Analysts project peak annual sales of ¥800 million to ¥1.2 billion (USD 110-170 million) for Aidea’s darunavir, representing meaningful contribution to the company’s anti-infective portfolio
Strategic Positioning
- Anti-Infective Focus: Strengthens Aidea’s position as a leading Chinese anti-infective specialist with capabilities spanning antibiotics, antivirals, and antifungals
- Import Substitution: Aligns with China’s national policy promoting domestic pharmaceutical production and reducing reliance on imported medicines
- Global Potential: Success in China’s large HIV market could support future regulatory submissions in other emerging markets facing similar treatment challenges
- Pipeline Diversification: Complements Aidea’s broader infectious disease pipeline, including novel antiviral candidates in development
Forward‑Looking Statements
This brief contains forward-looking statements regarding market opportunities, competitive dynamics, and commercial expectations. Actual results may differ due to reimbursement decisions, market adoption rates, and competitive responses from originator companies.-Fineline Info & Tech